Medgenics (MDGN)

[bob smith]

This open-label Phase IIa study will enroll up to 20 dialysis patients with anemia due to ESRD who have been receiving routine EPO injections three times per week. Each patient will receive an individually targeted initial dose of EPODURE Biopumps designed to produce levels of EPO that would replace the routine EPO injections over a period of 4-12 months

hmmmmmmm.....

will likely wait for the US drug application to be intiated!.......

gl